A Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Published:2019-07-19 Issue:2 Volume:5 Page:151-163
ISSN:2364-1754
Container-title:Pulmonary Therapy
language:en
Short-container-title:Pulm Ther

Author:

Prasse Antje,Ramaswamy Murali,Mohan Shaun,Pan Lin,Kenwright Andrew,Neighbors Margaret,Belloni Paula,LaCamera Peter P.

Funder

F. Hoffmann-La Roche Ltd

Genentech, Inc.

Publisher

Springer Science and Business Media LLC

Subject

Pulmonary and Respiratory Medicine,Respiratory Care

Link

http://link.springer.com/content/pdf/10.1007/s41030-019-0096-8.pdf

Reference44 articles.

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.

2. Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest. 2011;140(1):221–9.

3. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431–40.

4. Dempsey OJ, Kerr KM, Gomersall L, Remmen H, Currie GP. Idiopathic pulmonary fibrosis: an update. QJM. 2006;99(10):643–54.

5. Streiter RM. What differentiates normal lung repair and fibrosis? inflammation, resolution of repair, and fibrosis. Proc Am Thorac Soc. 2008;5:305–10.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The current landscape of antifibrotic therapy across different organs: A systematic approach;Pharmacological Research;2024-07

2. Emerging opportunities to treat idiopathic pulmonary fibrosis: Design, discovery, and optimizations of small-molecule drugs targeting fibrogenic pathways;European Journal of Medicinal Chemistry;2023-11

3. Oxy210, a Semi-Synthetic Oxysterol, Inhibits Profibrotic Signaling in Cellular Models of Lung and Kidney Fibrosis;Pharmaceuticals;2023-01-12

4. Vismodegib, a sonic hedgehog signalling blockade, ameliorates ovalbumin and ovalbumin/lipopolysaccharide-induced airway inflammation and asthma phenotypical models;Life Sciences;2022-12

5. Hedgehog pathway and its inhibitors in chronic obstructive pulmonary disease (COPD);Pharmacology & Therapeutics;2022-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3